GlassScriptPhysician profile
Stephen J Derbes
NPI 1689763302
$2,377.70
in general payments reported to CMS, 2019-2025
13 companies · $261 in 2025
The $261 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $126 · 2021: $268 · 2022: $356 · 2023: $553 · 2024: $612 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,228 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,228.36 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $833.83 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $317.56 | 2019-2024 | Tavneos, Prolia, Evenity |
| Novartis Pharmaceuticals Corporation | $297.50 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $198.00 | 2024-2025 | |
| Janssen Biotech, INC. | $169.23 | 2019-2022 | |
| Glaxosmithkline, LLC. | $165.79 | 2019-2024 | Benlysta |
| Ucb, INC. | $155.39 | 2021-2024 | Cimzia |
| Aurinia Pharma U.S., INC. | $64.50 | 2021-2024 | Lupkynis |
| Fresenius Kabi USA, LLC | $64.07 | 2024 | Idacio |
| Janssen Scientific Affairs, LLC | $60.45 | 2019-2025 | Tremfya |
| Alexion Pharmaceuticals, INC. | $19.33 | 2023 | Strensiq |
| Genzyme Corporation | $18.19 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $13.86 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Derbes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.